Dr. Eng Discusses the ADORE Trial in Rectal Cancer

Cathy Eng, MD
Published: Wednesday, Sep 19, 2018



Cathy Eng, MD, professor of gastrointestinal medical oncology, The University of Texas MD Anderson Cancer Center, discusses the ADORE trial in patients with rectal cancer.

The ADORE trial looked at the role of adjuvant chemotherapy based on a patient’s pathologic postoperative staging. In the trial, adjuvant oxaliplatin was added to leucovorin and 5-fluorouracil (5-FU; FOLFOX) and compared with leucovorin/5-FU alone. Researchers validated that there is an improvement in disease-free survival (DFS) for patients with stage III disease receiving FOLFOX, says Eng. This trial was done in patients with locally advanced rectal cancer.

The study met its primary endpoint of DFS, suggesting a clear benefit with the addition of oxaliplatin. Adjuvant chemotherapy remains a controversial topic in rectal cancer though, Eng says. The data from ADORE have been the most positive findings to date in support of adjuvant chemotherapy.
SELECTED
LANGUAGE


Cathy Eng, MD, professor of gastrointestinal medical oncology, The University of Texas MD Anderson Cancer Center, discusses the ADORE trial in patients with rectal cancer.

The ADORE trial looked at the role of adjuvant chemotherapy based on a patient’s pathologic postoperative staging. In the trial, adjuvant oxaliplatin was added to leucovorin and 5-fluorouracil (5-FU; FOLFOX) and compared with leucovorin/5-FU alone. Researchers validated that there is an improvement in disease-free survival (DFS) for patients with stage III disease receiving FOLFOX, says Eng. This trial was done in patients with locally advanced rectal cancer.

The study met its primary endpoint of DFS, suggesting a clear benefit with the addition of oxaliplatin. Adjuvant chemotherapy remains a controversial topic in rectal cancer though, Eng says. The data from ADORE have been the most positive findings to date in support of adjuvant chemotherapy.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 14th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®Apr 30, 20192.0
Oncology Consultations®: The Advancing Role of CAR T-Cell Therapies in Hematologic MalignanciesApr 30, 20191.5
Publication Bottom Border
Border Publication
x